Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

$ 13.99

4.5 (712) In stock

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

2 Contribution of Nonhuman Primate Models to Advances in Human Health, Nonhuman Primate Models in Biomedical Research: State of the Science and Future Needs

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Frontiers Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Biomedicines, Free Full-Text

Role of the humoral immune response during COVID-19: guilty or not guilty? - Mucosal Immunology

Vaccines that can protect against many coronaviruses could prevent another pandemic

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms